Celldex Therapeutics (NASDAQ:CLDX) shares are rising today on positive data in a Phase I/II study for a cancer vaccine.
Brain cancer patients who received the vaccine lived twice as long as those who received radiation and chemotherapy.
The vaccine works by spurring the immune system to attack cancer cells.
The Food & Drug Administration approved another cancer vaccine from Dendreon (DNDN) this year, and Bristol-Myers Squib (NYSE:BMY) is investigating similar treatments for skin cancer.
Pfizer (NYSE:PFE) ended its agreement to jointly develop the drug with Celldex earlier this month.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.